Comprehensive Care Improvement for Oncologic Fever and Neutropenia from a Pediatric Emergency Department

Overview

Journal Pediatr Qual Saf

Date 2024 Apr 4

PMID 38571520

Authors

Nicholas A Kuehnel

Erin McCreary

Sheryl L Henderson

Joshua P Vanderloo

Margo L Hoover-Regan

Brian Sharp

Joshua Ross

Affiliations

Soon will be listed here.

Abstract

Introduction: Rapid time to antibiotics (TTA) for pediatric patients with fever and neutropenia in an emergency department decreases in-hospital mortality. Additionally, national guidelines recommend outpatient antibiotic management strategies for low-risk fever and neutropenia (LRFN). This study had two specific aims: (1) improve the percent of patients with suspected fever and neutropenia who receive antibiotics within 60 minutes of arrival from 55% to 90%, and (2) develop and operationalize a process for outpatient management of LRFN patients by October 2018.

Methods: Using Lean methodologies, we implemented Plan-Do-Check-Act cycles focused on guideline development, electronic medical record reminders, order-set development, and a LRFN pathway as root causes for improvements. We used statistical process control charts to assess results.

Results: The project conducted from July 2016 to October 2018 showed special cause improvement in December 2016 on a G-chart. Monthly Xbar-chart showed improvement in average TTA from 68.5 minutes to 42.5 minutes. A P-chart showed improvement in patients receiving antibiotics within 60 minutes, from 55% to 86.4%. A LRFN guideline and workflow was developed and implemented in October 2017.

Conclusions: Implementation of guidelines, electronic medical record reminders, and order sets are useful tools to improve TTA for suspected fever and neutropenia. Utilizing more sensitive statistical process control charts early in projects with fewer patients can help recognize and guide process improvement. The development of workflows for outpatient management of LRFN may be possible, though it requires further study.

Citing Articles

Impact of a Clinical Decision Support Alert on Informed Consent Documentation in the Neonatal Intensive Care Unit.

Sangillo E, Jube-Desai N, El-Metwally D, Hughes Driscoll C Pediatr Qual Saf. 2024; 9(1):e713.

PMID: 38322296 PMC: 10843373. DOI: 10.1097/pq9.0000000000000713.

References

Gupta A, Swaroop C, Agarwala S, Pandey R, Bakhshi S . Randomized controlled trial comparing oral amoxicillin-clavulanate and ofloxacin with intravenous ceftriaxone and amikacin as outpatient therapy in pediatric low-risk febrile neutropenia. J Pediatr Hematol Oncol. 2009; 31(9):635-41. DOI: 10.1097/MPH.0b013e3181acd8cd. View

Villanueva M, August K . Early Discharge of Neutropenic Pediatric Oncology Patients Admitted With Fever. Pediatr Blood Cancer. 2016; 63(10):1829-33. DOI: 10.1002/pbc.26072. View

Miedema K, de Bont E, Oude Nijhuis C, van Vliet D, Kamps W, Tissing W . Validation of a new risk assessment model for predicting adverse events in children with fever and chemotherapy-induced neutropenia. J Clin Oncol. 2011; 29(7):e182-4. DOI: 10.1200/JCO.2010.32.7767. View

Klaassen R, Allen U, Doyle J . Randomized placebo-controlled trial of oral antibiotics in pediatric oncology patients at low-risk with fever and neutropenia. J Pediatr Hematol Oncol. 2000; 22(5):405-11. DOI: 10.1097/00043426-200009000-00004. View

Fletcher M, Hodgkiss H, Zhang S, Browning R, Hadden C, Hoffman T . Prompt administration of antibiotics is associated with improved outcomes in febrile neutropenia in children with cancer. Pediatr Blood Cancer. 2013; 60(8):1299-306. DOI: 10.1002/pbc.24485. View

Freifeld A, Bow E, Sepkowitz K, Boeckh M, Ito J, Mullen C . Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011; 52(4):e56-93. DOI: 10.1093/cid/cir073. View

Teuffel O, Ethier M, Alibhai S, Beyene J, Sung L . Outpatient management of cancer patients with febrile neutropenia: a systematic review and meta-analysis. Ann Oncol. 2011; 22(11):2358-2365. DOI: 10.1093/annonc/mdq745. View

Pulsipher M . Pediatric-specific guidelines for fever and neutropenia: a catalyst for improving care and focusing research. J Clin Oncol. 2012; 30(35):4292-3. DOI: 10.1200/JCO.2012.45.4629. View

McCavit T, Winick N . Time-to-antibiotic administration as a quality of care measure in children with febrile neutropenia: a survey of pediatric oncology centers. Pediatr Blood Cancer. 2011; 58(2):303-5. PMC: 3150359. DOI: 10.1002/pbc.23148. View

10.

Alexander S, Wade K, Hibberd P, Parsons S . Evaluation of risk prediction criteria for episodes of febrile neutropenia in children with cancer. J Pediatr Hematol Oncol. 2002; 24(1):38-42. DOI: 10.1097/00043426-200201000-00011. View

11.

Klaassen R, Goodman T, Pham B, Doyle J . "Low-risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol. 2000; 18(5):1012-9. DOI: 10.1200/JCO.2000.18.5.1012. View

12.

Rosa R, Goldani L . Cohort study of the impact of time to antibiotic administration on mortality in patients with febrile neutropenia. Antimicrob Agents Chemother. 2014; 58(7):3799-803. PMC: 4068526. DOI: 10.1128/AAC.02561-14. View

13.

Salstrom J, Coughlin R, Pool K, Bojan M, Mediavilla C, Schwent W . Pediatric patients who receive antibiotics for fever and neutropenia in less than 60 min have decreased intensive care needs. Pediatr Blood Cancer. 2015; 62(5):807-15. PMC: 4413050. DOI: 10.1002/pbc.25435. View

14.

Sezgin G, Acipayam C, Ozkan A, Bayram I, Tanyeli A . Meropenem versus piperacillin-tazobactam as empiric therapy for febrile neutropenia in pediatric oncology patients. Asian Pac J Cancer Prev. 2014; 15(11):4549-53. DOI: 10.7314/apjcp.2014.15.11.4549. View

15.

Vardakas K, Samonis G, Chrysanthopoulou S, Bliziotis I, Falagas M . Role of glycopeptides as part of initial empirical treatment of febrile neutropenic patients: a meta-analysis of randomised controlled trials. Lancet Infect Dis. 2005; 5(7):431-9. DOI: 10.1016/S1473-3099(05)70164-X. View

16.

Manji A, Lehrnbecher T, Dupuis L, Beyene J, Sung L . A systematic review and meta-analysis of anti-pseudomonal penicillins and carbapenems in pediatric febrile neutropenia. Support Care Cancer. 2011; 20(10):2295-304. DOI: 10.1007/s00520-011-1333-3. View

17.

Cash T, Deloach T, Graham J, Shirm S, Mian A . Standardized process used in the emergency department for pediatric oncology patients with fever and neutropenia improves time to the first dose of antibiotics. Pediatr Emerg Care. 2014; 30(2):91-3. DOI: 10.1097/PEC.0000000000000077. View

18.

Volpe D, Harrison S, Damian F, Rachh P, Kahlon P, Morrissey L . Improving timeliness of antibiotic delivery for patients with fever and suspected neutropenia in a pediatric emergency department. Pediatrics. 2012; 130(1):e201-10. DOI: 10.1542/peds.2012-0153. View

19.

Bow E, Rotstein C, Noskin G, Laverdiere M, Schwarer A, Segal B . A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies. Clin Infect Dis. 2006; 43(4):447-59. DOI: 10.1086/505393. View

20.

Manji A, Beyene J, Dupuis L, Phillips R, Lehrnbecher T, Sung L . Outpatient and oral antibiotic management of low-risk febrile neutropenia are effective in children--a systematic review of prospective trials. Support Care Cancer. 2012; 20(6):1135-45. DOI: 10.1007/s00520-012-1425-8. View